Pre-surgery chemotherapy and MRI accuracy for staging muscle-invasive bladder cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares MRI staging results to final surgical pathology in patients with cT2 urothelial bladder cancer who either receive neoadjuvant chemotherapy (NAC) before radical cystectomy or proceed directly to surgery. All participants undergo MRI before cystectomy, and MRI interpretations are compared with histopathology to measure diagnostic accuracy. The study specifically examines whether tissue changes caused by NAC alter MRI appearance and affect staging reliability. Results will inform how well MRI reflects true tumor stage after chemotherapy and may guide imaging interpretation and surgical planning.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients diagnosed with cT2 urothelial carcinoma of the urinary bladder, according to the TNM classification, who give informed, written consent on participation in the study and approve all its requirements.

Exclusion Criteria:

* Patients who have received pelvic radiotherapy.
* Previous open or laparoscopic pelvic surgery.
* Patients with contraindications to MRI.
* Patients who are unfit for or refuse radical cystectomy.
* Ineligibility to cisplatin.
* squamous differentiation in the histopathology

Where it's running

• Urology Department, Faculty of Medicine, Assiut University
  Asyut, Asyut Governorate, Egypt Recruiting
• Urology Department, Faculty of Medicine, Assiut University
  Asyut, Asyut Governorate, Egypt Not yet recruiting

Study contacts

• Principal investigator: Amr Darwish, Lecturer — Assiut University
• Study coordinator: Hamza Elhashamy, MBBCh
• Email: Hamza.Ahmed00099@med.aun.edu.eg
• Phone: +201028635437

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FDG PET/CT for Muscle-Invasive Bladder Cancer: Baseline Staging and Chemotherapy Response

  This study tests how well 18F-FDG PET/CT can stage muscle-invasive bladder cancer and predict how patients respond to neoadjuvant chemotherapy.

  Recruiting University Hospital of Ferrara · Ferrara · NCT07750470

• Enfortumab vedotin plus pembrolizumab to help people with muscle-invasive bladder cancer keep their bladder

  This trial tests whether giving enfortumab vedotin together with pembrolizumab can let people with muscle-invasive bladder cancer avoid bladder removal.

  Recruiting at 68 sites Phase 2 Astellas Pharma Inc · Little Rock, Arkansas and 67 other locations · NCT07475806

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

• Combining rutin with immunotherapy and chemotherapy for bladder cancer treatment

  This study is testing if adding rutin to standard bladder cancer treatments can help patients whose cancer hasn't responded to chemotherapy feel better and improve their outcomes.

  Recruiting Phase 1 First Affiliated Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT06916494

• Tetra-modality bladder-preservation approach in muscle-invasive bladder cancer

  This trial tests whether adding the immunotherapy drug avelumab to tumor removal, chemotherapy, and radiation can help people with muscle-invasive bladder cancer keep their bladder.

  Recruiting Phase 2 American University of Beirut Medical Center · Beirut, Beirut · NCT06686381

• Combination therapy for high-risk muscle-invasive bladder cancer

  This study is testing if a combination of two cancer drugs can help people with high-risk bladder cancer stay cancer-free after surgery.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06682728

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.